Notal Vision

Company Overview

Snapshot

Founded in August 2000, Notal Vision operates with 51–200 employees and has raised a total of $94.05 million across 6 funding rounds from 6 investors. The company achieved a significant milestone in December 2018 when its Home OCT was granted Breakthrough Device Designation by the FDA and selected for the FDA's OCT Innovation Pilot program.

Business overview

Notal Vision develops a cloud-based platform leveraging AI algorithms for diagnostic decision support in ophthalmology. The company's core technology facilitates at-home testing and patient-activated treatment for retinal diseases. Its offerings include ForeseeHome, an FDA-approved home monitoring test for early detection of wet age-related macular degeneration (AMD), and home optical coherence tomography (OCT) solutions for viewing retinal anatomy. Notal Vision serves the healthcare industry, specifically targeting ophthalmologists and patients with age-related eye diseases, operating within the Health Tech & Life Sciences sector with a focus on Digital Medical Diagnostics.

Strategic signal

In March 2024, Notal Vision was highlighted for its world-class technological solutions utilizing artificial intelligence in eye care, underscoring the company's continued innovation in digital healthcare. This signals a strong commitment to advancing AI-driven diagnostic tools, which is critical for improving patient outcomes and expanding access to specialized eye care.

Company Intelligence Q&A

What is Notal Vision's primary focus?

Notal Vision focuses on remote patient monitoring for retinal diseases, utilizing a cloud-based platform with AI algorithms for diagnostic decision support and at-home testing.

When was Notal Vision founded?

Notal Vision was founded in August 2000.

What significant regulatory milestone did Notal Vision achieve with its Home OCT?

In December 2018, Notal Vision's Home OCT was granted Breakthrough Device Designation by the FDA and was selected to participate in the FDA's OCT Innovation Pilot program.

Which investors participated in Notal Vision's June 2021 funding round?

In June 2021, Notal Vision received funding from investors including.

What is ForeseeHome?

ForeseeHome is an FDA-approved home monitoring test developed by Notal Vision that supports earlier detection of wet age-related macular degeneration (AMD) in individuals with intermediate dry AMD.